Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peginterferon alfa-2b (Y-shaped pegylation) - Xiamen Amoytop Biotech

Next Previous
Drug Profile

Peginterferon alfa-2b (Y-shaped pegylation) - Xiamen Amoytop Biotech

Alternative Names: Mipeginterferon alfa-2b - Xiamen Amoytop Biotech; Pegberon; PEGBING; Y-shaped pegylated interferon alfa-2b; YPEG-rhIFNα-2b - Xiamen Amoytop Biotech; Ypeginterferon alfa-2b - Xiamen Amoytop Biotech; Ypeginterferon alpha-2b - Xiamen Amoytop Biotech

Latest Information Update: 18 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xiamen Amoytop Biotech
  • Class Antihaemorrhagics; Antineoplastics; Antiretrovirals; Antivirals; Immunotherapies; Interferons; Polyethylene glycols; Skin disorder therapies
  • Mechanism of Action Interferon alpha-2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C
  • Phase III Hepatitis B
  • Phase II Essential thrombocythaemia

Most Recent Events

  • 18 Dec 2024 Peginterferon alfa-2b (Y-shaped pegylation) is still in phase III trial in Hepatitis B (Combination therapy, Treatment-naive) in China (SC) (NCT04846491)
  • 15 Nov 2024 Pharmacodynamics data from the phase III ANCHOR trial presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024)
  • 14 Nov 2024 Efficacy data from phase III clinical trials in Hepatitis B presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases (ASLD-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top